151 related articles for article (PubMed ID: 38105495)
1. Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells.
Rawal P; Tripathi DM; Hemati H; Kumar J; Tyagi P; Sarin SK; Nain V; Kaur S
Liver Int; 2024 Feb; 44(2):614-624. PubMed ID: 38105495
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.
Fei L; Sun S; Yang Q; Huang Y; Li Q; Tao S; Chen L
Discov Med; 2024 Jun; 36(185):1169-1179. PubMed ID: 38926103
[TBL] [Abstract][Full Text] [Related]
3. Linc00152 promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Deng X; Zhao XF; Liang XQ; Chen R; Pan YF; Liang J
Biomed Pharmacother; 2017 Jun; 90():100-108. PubMed ID: 28343069
[TBL] [Abstract][Full Text] [Related]
4. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
5. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.
Salpini R; Surdo M; Cortese MF; Palumbo GA; Carioti L; Cappiello G; Spanò A; Trimoulet P; Fleury H; Vecchiet J; Pasquazzi C; Mirabelli C; Scutari R; Sacco A; Alkhatib M; Missale G; Francioso S; Sarmati L; Andreoni M; Angelico M; Ceccherini-Silberstein F; Levrero M; Perno CF; Belloni L; Svicher V
Clin Microbiol Infect; 2019 Jul; 25(7):906.e1-906.e7. PubMed ID: 30472417
[TBL] [Abstract][Full Text] [Related]
6. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
[TBL] [Abstract][Full Text] [Related]
7. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus X protein-elevated MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis.
Gao Y; Feng J; Yang G; Zhang S; Liu Y; Bu Y; Sun M; Zhao M; Chen F; Zhang W; Ye L; Zhang X
Hepatology; 2017 Nov; 66(5):1413-1429. PubMed ID: 28608964
[TBL] [Abstract][Full Text] [Related]
10. HBx mediated Increase of SIRT1 Contributes to HBV-related Hepatocellular Carcinoma Tumorigenesis.
Wang Q; Cheng ST; Chen J
Int J Med Sci; 2020; 17(12):1783-1794. PubMed ID: 32714081
[No Abstract] [Full Text] [Related]
11. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
12. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
13. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription.
Deng JJ; Kong KE; Gao WW; Tang HV; Chaudhary V; Cheng Y; Zhou J; Chan CP; Wong DK; Yuen MF; Jin DY
Biochim Biophys Acta Gene Regul Mech; 2017 Apr; 1860(4):491-501. PubMed ID: 28242208
[TBL] [Abstract][Full Text] [Related]
14. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
Yang HC; Chen PJ
Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
[TBL] [Abstract][Full Text] [Related]
15. IFN-α2b inhibits the ethanol enriched-HBV cccDNA through blocking a positive feedback loop of HBx/MSL2/cccDNA/HBV/HBx in liver.
Liu Z; Wang J; Yuan H; Liu L; Bu Y; Zhao M; Yang G; Feng J; Liu Y; Li J; He Q; Zhang X
Biochem Biophys Res Commun; 2020 Jun; 527(1):76-82. PubMed ID: 32446394
[TBL] [Abstract][Full Text] [Related]
16. PreS1BP mediates inhibition of Hepatitis B virus replication by promoting HBx protein degradation.
Wang J; Yuan X; Wang Y; Zhang Y; Han M; Lu H; Liu S; Zhang Y; Ge F; Liu Y; Cheng J
Virus Res; 2024 Mar; 341():199326. PubMed ID: 38253259
[TBL] [Abstract][Full Text] [Related]
17. MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells.
Yu G; Chen X; Chen S; Ye W; Hou K; Liang M
J Transl Med; 2016 May; 14(1):122. PubMed ID: 27150195
[TBL] [Abstract][Full Text] [Related]
18. Parvulin 14 and Parvulin 17 Bind to HBx and cccDNA and Upregulate Hepatitis B Virus Replication from cccDNA to Virion in an HBx-Dependent Manner.
Saeed U; Kim J; Piracha ZZ; Kwon H; Jung J; Chwae YJ; Park S; Shin HJ; Kim K
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567987
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient.
Kato Y; Tabata H; Sato K; Nakamura M; Saito I; Nakanishi T
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638909
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
